Drug Allergy — Penicillin and Cross-Reactivity

• Hapten Formation and Immune Recognition: Penicillins are small molecules (~356 Da) that cannot directly activate T and B lymphocytes; they function as haptens by covalently binding to host carrier proteins (albumin, red blood cells, tissue macromolecules) through nucleophilic attack on the highly reactive beta-lactam ring. The penicilloyl moiety (formed from the opened beta-lactam ring) represents the major determinant, while minor determinants (including intact penicillin, penicillenic acid, and penilloic acid) are formed through alternative degradation pathways. Penicilloyl-carrier protein complexes present conformational epitopes recognized by preexisting or newly generated IgE, IgG, or T-cell receptors, initiating hypersensitivity responses. This explains why allergic reactions can occur on re-exposure after prior sensitization—the immune system has already generated memory B and T cells against penicilloyl epitopes.

• IgE-Mediated Immediate Hypersensitivity (Type I): Cross-linking of IgE antibodies bound to penicilloyl-carrier complexes on mast cell and basophil surfaces triggers rapid degranulation through Fc-epsilon receptor I (FcεRI) signaling, releasing preformed mediators (histamine, tryptase, heparin) and newly synthesized mediators (leukotriene C4, prostaglandin D2, platelet-activating factor). These mediators bind to specific G-protein-coupled receptors (H1 and H2 histamine receptors, cysteinyl leukotriene receptors, PAF receptors) on endothelial cells, smooth muscle, and respiratory epithelium, causing vasodilation, increased vascular permeability, bronchospasm, and angioedema—manifesting clinically within minutes as anaphylaxis. Penicillins preferentially generate IgE to major determinants (penicilloyl), while minor determinants are more immunogenic in certain populations and associated with more severe reactions in some studies.

• IgG-Mediated Cytotoxic Reactions (Type II): Penicilloyl hapten modification of red blood cell, platelet, or white blood cell surfaces creates neoantigen epitopes recognized by IgG antibodies, which then activate the classical complement cascade (C1q binding) and antibody-dependent cellular cytotoxicity (ADCC). Opsonization by IgG and complement deposition (C3b, C4b) target cells for destruction by macrophages in the spleen and liver through Fc-receptor and complement-receptor engagement. This mechanism produces drug-induced hemolytic anemia, thrombocytopenia, or agranulocytosis, typically occurring after 1-2 weeks of therapy as IgG antibody titers rise. The kinetics distinguish this from immediate reactions and explain why these cytopenias develop later during treatment courses.

• T-Cell-Mediated Delayed Hypersensitivity (Type IV): Penicilloyl-carrier complexes are processed by antigen-presenting cells and presented to T cells via major histocompatibility complex (MHC) molecules. CD8+ cytotoxic T lymphocytes recognize penicilloyl-modified self-peptides presented on MHC-I, while CD4+ T helper cells recognize penicilloyl-peptide complexes on MHC-II, generating Th1 (IFN-gamma-producing) and Th17 (IL-17-producing) responses. Activated T cells infiltrate skin and other tissues, recruiting additional inflammatory cells and causing delayed rashes, Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug reaction with eosinophilia and systemic symptoms (DRESS). HLA alleles (particularly HLA-B*5701, HLA-A*3101, others) associate with increased risk for severe delayed reactions through enhanced peptide-MHC binding affinity for penicilloyl-modified epitopes, explaining genetic predisposition in certain populations.

• Structural Basis for Cross-Reactivity: The beta-lactam ring core structure is essential for antimicrobial activity but also represents a common epitope across penicillins, cephalosporins, carbapenems, and monobactams. Penicillins and cephalosporins share a beta-lactam ring attached to a thiazolidine ring (penicillins) or dihydrothiazine ring (cephalosporins), with differences in R-group side chains that primarily determine specificity and toxicity. IgE and T-cell receptors with broad specificity for the beta-lactam core structure cross-react with multiple beta-lactam classes; however, if the immune response is directed against penicillin-specific determinants (penicilloyl hapten or unique side chains), cross-reactivity decreases. First-generation cephalosporins have side-chain homology to penicillins, increasing cross-reactivity risk (~1-3% in penicillin-allergic patients), while third-generation cephalosporins (lacking side-chain similarity) show minimal cross-reactivity (~0.1%). Carbapenems (meropenem, imipenem) share the beta-lactam ring but have a different fused ring system and minimal side-chain homology, resulting in very low cross-reactivity (~1-3%) even with documented penicillin allergy. Monobactams (aztreonam) contain only the beta-lactam ring without the fused ring system, showing almost no cross-reactivity with penicillins unless the patient is also allergic to ceftazidime (which shares an R-group side chain with aztreonam).

• Non-IgE Mediated Reactions: Penicillins can trigger reactions without IgE involvement through direct mast cell activation, complement-mediated reactions (especially with high-dose IV penicillin), and drug-induced pseudoallergy where histamine release occurs without IgE cross-linking. These mechanisms explain anaphylaxis-like reactions in patients with no documented IgE antibodies and reactions on first exposure (before IgE can be generated). Excipients (including carboxymethylcellulose in some formulations) can trigger reactions independently of the beta-lactam core.

• Prior Penicillin Exposure and Sensitization: Initial exposure to penicillin (or cross-reactive beta-lactams) generates primary immune responses leading to sensitization; subsequent exposures reactivate memory B and T cells for rapid secondary responses. Most documented penicillin allergies develop in patients with previous exposure, though first-exposure reactions can occur if the patient has prior exposure to structurally similar compounds (cephalosporins, environmental sources). The likelihood of sensitization increases with higher doses, longer duration of therapy, and route (IV > IM > oral), though oral penicillins remain common culprits because of their widespread use.

• Genetic Predisposition and HLA Associations: Specific HLA alleles strongly associate with increased risk for severe penicillin-related delayed reactions; HLA-B*5701 increases risk for abacavir hypersensitivity (not directly penicillin but demonstrates HLA-drug interaction), while HLA-A*3101 associates with carbamazepine SJS and other drug reactions. Polymorphisms in genes encoding cytochrome P450 enzymes (CYP3A4, CYP2C9) and N-acetyltransferase (NAT) affect beta-lactam metabolism and hapten formation, influencing individual susceptibility. First-degree relatives of patients with severe drug reactions show increased risk, supporting genetic contribution to drug-processing capacity and immune response magnitude.

• Age and Timing Factors: Penicillin allergy is reported more commonly in adults than children, partly because older individuals have had more cumulative exposures; however, true IgE-mediated reactions (anaphylaxis) can occur at any age. Atopic individuals (history of asthma, eczema, allergic rhinitis, food allergies) show higher risk for IgE-mediated penicillin reactions, as they tend to mount larger IgE responses to multiple antigens. The interval between exposures influences reaction risk—reactions are more common with closely spaced re-exposures (reactivation of memory cells) than with widely separated exposures (waning of antibody titers).

• Concurrent Infections and Immune Activation: Active viral infections (especially mononucleosis caused by Epstein-Barr virus) dramatically increase risk for penicillin rashes; classic teaching describes amoxicillin-induced rash in infectious mononucleosis (which occurs in ~90% of EBV-infected patients given amoxicillin but is not a true IgE-mediated penicillin allergy—rather, it represents circulating immune complex deposition or cross-reactive T-cell responses). This phenomenon explains why patients may tolerate penicillins initially but react during concurrent infections, and why the rash typically appears 7-10 days into therapy (timing of peak immune response).

• Route of Administration: Parenteral penicillin (IV, IM) carries higher risk for severe reactions than oral formulations due to higher bioavailability and more complete epitope presentation. IV penicillin G achieves higher serum concentrations and may trigger complement-mediated reactions at peak levels, while oral amoxicillin provides lower and more gradual absorption, reducing mast cell activation intensity.

• Structural Features Affecting Allergenicity: Side-chain modifications of penicillins influence immunogenicity; ampicillin and amoxicillin (with amino-phenyl side chains) tend to generate stronger immune responses than penicillin G (with benzyl side chain), explaining higher reported allergy rates with aminopenicillins. Methicillin (now discontinued) was particularly immunogenic, with high rates of delayed hypersensitivity. Lipophilic side chains enhance hepatic metabolism and may alter hapten formation pathways.

• Immediate Anaphylaxis (IgE-Mediated, Minutes to 1 Hour): Onset within minutes to 30 minutes of exposure defines true anaphylaxis. Urticaria and pruritus appear first as mast cell degranulation releases histamine locally in skin (H1-mediated vasodilation and increased vascular permeability). Angioedema affecting lips, tongue, throat (indicating C1-esterase inhibitor and bradykinin release) presents as non-pitting edema and constitutes an airway emergency. Bronchospasm manifests as dyspnea, wheezing, and stridor as leukotrienes constrict bronchial smooth muscle and increase mucus secretion. Gastrointestinal symptoms (cramping abdominal pain, nausea, vomiting, diarrhea) result from histamine H1 and H2 receptor-mediated smooth muscle contraction and increased secretion. Cardiovascular collapse with hypotension (systolic BP <90 mmHg) and shock occurs from profound vasodilation (via H2-mediated endothelial adenylyl cyclase) and increased vascular permeability causing intravascular volume depletion; arrhythmias (tachycardia, bradycardia) result from catecholamine surges and direct mediator effects on cardiac tissue. Syncope, altered mental status, death can ensue within minutes without immediate intervention.

• Serum Sickness-Like Reactions (Immune Complex-Mediated, 7-21 Days): Circulating immune complexes of penicilloyl-IgG and complement deposit in small blood vessels, triggering Type III hypersensitivity. Fever appears 7-14 days after initiating therapy as immune complexes activate complement and stimulate macrophage IL-6 and TNF-alpha production. Urticarial or maculopapular rash (often pruritic, non-blanching) appears on trunk and extremities from vasculitis causing endothelial damage. Arthralgia and arthritis (knees, ankles, wrists) result from immune complex deposition in synovial tissue and trigger of complement cascade with neutrophil infiltration. Lymphadenopathy appears as immune complex accumulation and lymphocyte activation in regional nodes. Systemic symptoms (malaise, myalgia) reflect IL-1, IL-6, and TNF-alpha release. Notably, this reaction typically resolves within 1-2 weeks of drug discontinuation and is not associated with true IgE sensitization, though patients often incorrectly receive "penicillin allergy" labels.

• Delayed Hypersensitivity Rash (Type IV, 5-21 Days): T-cell infiltration of skin produces maculopapular exanthem typically appearing 5-10 days after initiating penicillin therapy (timing allows antigen presentation and T-cell activation). The rash characteristically appears on trunk and extremities, may involve palms and soles, and can progress to confluent erythema. Associated symptoms include low-grade fever and occasional systemic symptoms. This reaction does not represent true penicillin allergy in most cases and does not contraindicate future penicillin use (critical board point).

• Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN): These severe T-cell-mediated reactions occur in genetically predisposed patients carrying specific HLA alleles. SJS presents with blistering and erosion of <10% body surface area (BSA), while TEN involves >30% BSA. Prodrome includes fever, malaise, and pharyngitis (viral-like syndrome) followed by painful blisters on lips, oral mucosa, genitalia, and eyes. Target lesions (concentric rings of erythema with pale center) on hands and feet are characteristic. Mucous membrane involvement is prominent, with erosive oral ulcers, conjunctivitis, and urethritis. Systemic manifestations include hepatitis (elevated transaminases), renal dysfunction, and sepsis if infection develops. Mortality in TEN reaches 20-40% despite supportive care.

• Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): This severe T-cell-mediated reaction typically occurs 2-8 weeks after penicillin exposure (delayed onset relative to simple rashes). Facial edema and lymphadenopathy are cardinal features. Atypical lymphocytes on blood smear and eosinophilia (often >1500/μL or >11% of WBC) distinguish this from other drug rashes. Hepatitis (markedly elevated transaminases, sometimes >1000 IU/L) and renal dysfunction occur as organ-specific T-cell infiltration develops. Fever is prominent and may be the presenting symptom. Viral reactivation (EBV, CMV, HHV-6, HHV-7) occurs in 50-80% of DRESS cases, detected by PCR or serology, and may contribute to pathogenesis.

• Drug-Induced Hemolytic Anemia (Type II Cytotoxic): This occurs in patients receiving prolonged penicillin therapy (classically after 1-2 weeks of high-dose IV penicillin). Anemia symptoms (fatigue, dyspnea, jaundice) develop gradually as hemolysis accelerates. Lab findings show decreased hemoglobin, **elevated

Step 1 — risk-stratify the history (AAAAI/ACAAI Joint Task Force drug allergy practice parameter)

• Reaction phenotype and latency: the single most informative data are timing (minutes vs. days), morphology (urticaria/angioedema vs. exanthem vs. blistering), and whether treatment or hospitalization was required. Childhood "rash only" more than a decade ago, isolated GI upset, or family history of allergy are not IgE-mediated histories.
• PENFAST clinical decision rule: a validated bedside tool using time since reaction (recent reactions score higher), anaphylaxis/angioedema or severe cutaneous adverse reaction, and whether treatment was required; the lowest scores identify patients with very low likelihood of a positive test who can proceed to direct oral challenge.

Step 2 — acute-phase confirmation when the reaction is happening

• Anaphylaxis is a clinical diagnosis (NIAID/FAAN criteria): acute onset with skin/mucosal involvement plus respiratory compromise or hypotension, or hypotension after a known allergen. Serum tryptase drawn within a few hours of onset and compared with a convalescent baseline supports mast-cell degranulation, but a normal value does not exclude anaphylaxis.

Step 3 — testing for IgE sensitization

• Penicillin skin testing: percutaneous then intradermal testing with benzylpenicilloyl-polylysine (major determinant), a minor-determinant/penicillin G reagent, and often amoxicillin, with histamine positive and saline negative controls. A wheal at least 3 mm larger than the negative control with surrounding erythema is positive.
• Graded oral amoxicillin challenge is the gold standard: performed after negative skin testing (or directly in low-risk histories), it carries a very high negative predictive value and is what formally delabels the patient.
• In vitro penicillin-specific IgE has poor sensitivity and cannot be used to exclude allergy.

Step 4 — delayed/severe reactions have different tests

• Skin prick and intradermal testing are invalid and unsafe in SJS/TEN, DRESS, or AGEP; use patch testing or delayed intradermal readings only for benign delayed exanthems.
• DRESS: RegiSCAR scoring with eosinophilia, atypical lymphocytes, transaminitis, and HHV-6/CMV/EBV PCR. SJS/TEN: biopsy showing full-thickness epidermal necrosis with sparse infiltrate; SCORTEN estimates mortality. Type II cytopenias: positive direct antiglobulin test with spherocytes and elevated indirect bilirubin/LDH, low haptoglobin.

Immediate stabilization of anaphylaxis (AAAAI/ACAAI and WAO anaphylaxis guidance)

• Stop the drug and give epinephrine first: epinephrine 0.3–0.5 mg IM (0.01 mg/kg, max 0.5 mg) into the anterolateral thigh, repeated every 5–15 minutes as needed. Alpha-1 vasoconstriction reverses vasodilation and mucosal edema; beta-2 activity relieves bronchospasm and stabilizes mast cells. There is no absolute contraindication to epinephrine in anaphylaxis.
• Adjuncts, never substitutes: supine positioning with legs elevated, high-flow oxygen, large-volume isotonic crystalloid for distributive shock, inhaled beta-2 agonist (albuterol) for bronchospasm, H1 antihistamine (diphenhydramine or cetirizine) for itch and urticaria only. Glucocorticoids do not treat the acute event and have not been shown to prevent biphasic reactions.
• Refractory hypotension: IV epinephrine infusion; add glucagon if the patient is on a beta blocker and epinephrine is ineffective. Early airway assessment for laryngeal angioedema — intubate before edema makes it impossible.
• Before discharge: epinephrine autoinjector prescription, written allergen documentation, and allergy/immunology referral.

Definitive management — delabeling, not lifelong avoidance

• Direct oral amoxicillin challenge for low-risk histories and skin testing followed by challenge for higher-risk IgE histories, per the AAAAI/ACAAI drug allergy practice parameter; successful challenge removes the label from the chart.
• Beta-lactam selection is side-chain based: cephalosporins with side chains dissimilar to the culprit penicillin (notably cefazolin, which shares a side chain with no penicillin) are recommended for surgical prophylaxis and most infections in penicillin-allergic patients per ASHP/IDSA/SIS/SHEA prophylaxis guidance. Carbapenems are tolerated by the great majority. Aztreonam is safe except in ceftazidime allergy (shared side chain).
• Rapid induction of drug tolerance (desensitization) when penicillin is uniquely superior — syphilis in pregnancy and neurosyphilis (CDC STI Treatment Guidelines), enterococcal or streptococcal endocarditis, congenital syphilis. Performed in a monitored setting with escalating doses; tolerance is temporary and lost once the drug is stopped.

Contraindicated

• Desensitization or re-challenge after SJS/TEN, DRESS, AGEP, or drug-induced cytopenia — absolute contraindication.
• Reflexive vancomycin/fluoroquinolone/clindamycin substitution for an unverified label, and treating anaphylaxis with antihistamines or steroids while withholding epinephrine.

Emergencies

• Laryngeal angioedema and asphyxia: mediator-driven mucosal edema of the supraglottic airway; signaled by stridor, hoarseness, tongue or uvular swelling, or a sensation of throat closure. Secure the airway early — a true emergency.
• Anaphylactic shock and cardiac arrest: massive vasodilation with capillary leak causes profound preload loss; hypotension unresponsive to fluids, or arrest, follows delayed epinephrine. Emergency.
• Biphasic anaphylaxis: recurrence hours after apparent resolution without re-exposure, from newly synthesized mediators; mandates a period of observation after severe or epinephrine-requiring reactions. Emergency if it occurs.
• TEN: >30% BSA epidermal detachment with positive Nikolsky sign; deaths result from hypovolemia, thermoregulatory failure, and sepsis (often Staphylococcus aureus or Pseudomonas) through the denuded barrier. Manage in a burn unit. Emergency.
• DRESS with fulminant hepatitis or myocarditis: eosinophil- and T-cell–mediated organ infiltration; rising transaminases with coagulopathy or a falling ejection fraction signals it. Emergency.

Delayed and organ-specific

• Acute interstitial nephritis: T-cell–mediated tubulointerstitial infiltration (classically methicillin, also nafcillin/penicillins); rising creatinine with fever, rash, eosinophilia, sterile pyuria, and WBC casts.
• Immune hemolytic anemia and cytopenias: hapten-coated red cells or platelets cleared by splenic macrophages after 1–2 weeks of high-dose therapy; positive direct antiglobulin test, spherocytes, high LDH, low haptoglobin, and neutropenia on serial counts.
• Ocular and cutaneous sequelae of SJS/TEN: conjunctival scarring, symblepharon, dry eye and blindness; dyspigmentation and nail loss.
• Autoimmune sequelae of DRESS: months later — thyroiditis/hypothyroidism, type 1 diabetes; check thyroid function on follow-up.

Complications of mislabeling and of treatment

• Consequences of an unverified penicillin allergy label: broader-spectrum substitutes (vancomycin, fluoroquinolones, clindamycin) are associated with more Clostridioides difficile colitis, MRSA and VRE acquisition, treatment failure, longer stays, and higher cost — the reason antibiotic stewardship programs and the CDC promote delabeling.
• Reaction during desensitization: breakthrough urticaria or anaphylaxis during dose escalation; requires monitored setting with epinephrine immediately available. Tolerance is lost after the course ends.

• Timing separates mechanism from mimic: urticaria/angioedema/hypotension within minutes to an hour = IgE-mediated; a morbilliform exanthem appearing 5–10 days in is T-cell mediated and generally not a contraindication to future beta-lactams.
• Amoxicillin rash in infectious mononucleosis is the classic distractor: a widespread maculopapular eruption in a teenager with pharyngitis, posterior cervical lymphadenopathy, and atypical lymphocytes is not penicillin allergy — do not label the patient.
• Single best next step in a reported allergy needing penicillin: refer for penicillin skin testing followed by graded oral amoxicillin challenge (or direct oral challenge in a low-risk history) per the AAAAI/ACAAI practice parameter; a negative challenge delabels.
• The association examiners love: pregnant patient with syphilis and penicillin allergy → penicillin desensitization, not doxycycline (teratogenic/contraindicated in pregnancy) and not azithromycin (resistance, unreliable fetal treatment). CDC STI guidelines are explicit here.
• Epinephrine IM is always the first drug in anaphylaxis — 0.3 mg IM in the anterolateral thigh. Antihistamines and glucocorticoids are adjuncts; choosing IV diphenhydramine or methylprednisolone as the initial step is the trap.
• Cross-reactivity is about side chains, not the beta-lactam ring: cefazolin shares its side chain with no penicillin and is the preferred cephalosporin in these patients; carbapenems are almost always tolerated; aztreonam is safe unless the patient reacts to ceftazidime (shared side chain).
• Penicillin-specific IgE wanes over time, so a remote childhood reaction most often tests negative — an old label should prompt evaluation, not lifelong vancomycin.
• Severe delayed reactions are an absolute stop: after SJS/TEN, DRESS, AGEP, or drug-induced hemolysis, never skin test, challenge, or desensitize. Recognize DRESS by facial edema, eosinophilia, atypical lymphocytes, and transaminitis 2–8 weeks after exposure; recognize acute interstitial nephritis by fever, rash, eosinophiluria, and WBC casts.